Skip to main content
NCBI home page
Journal of Neurology, Neurosurgery, and Psychiatry logoLink to Journal of Neurology, Neurosurgery, and Psychiatry
. 1976 Oct;39(10):941–951. doi: 10.1136/jnnp.39.10.941

Dopamine correlates of neurological and psychological status in untreated Parkinsonism1

Margaret M Hoehn 1,2,3, T J Crowley 1,2,3, C O Rutledge 1,2,3
PMCID: PMC492496  PMID: 1003240

Abstract

Thirty-seven untreated Parkinsonism patients showed significant positive correlations among decreased excretion of free dopamine, MMPI scores indicative of schizophrenic-like looseness of thinking, and the severity of all Parkinsonism signs except tremor. The data could indicate that abnormalities of dopamine metabolism may underlie both the motor and mental abnormalities of Parkinsonism.

Full text

PDF
941

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. ANTON A. H., SAYRE D. F. THE DISTRIBUTION OF DOPAMINE AND DOPA IN VARIOUS ANIMALS AND A METHOD FOR THEIR DETERMINATION IN DIVERSE BIOLOGICAL MATERIAL. J Pharmacol Exp Ther. 1964 Sep;145:326–336. [PubMed] [Google Scholar]
  2. Abramsky O., Carmon A., Lavy S. Combined treatment of Parkinsonian tremor with propranolol and levodopa. J Neurol Sci. 1971 Dec;14(4):491–494. doi: 10.1016/0022-510x(71)90183-3. [DOI] [PubMed] [Google Scholar]
  3. BARBEAU A., MURPHY G. F., SOURKES T. L. Excretion of dopamine in diseases of basal ganglia. Science. 1961 May 26;133(3465):1706–1707. doi: 10.1126/science.133.3465.1706-a. [DOI] [PubMed] [Google Scholar]
  4. BISCHOFF F., TORRES A. Determination of urine dopamine. Clin Chem. 1962 Aug;8:370–377. [PubMed] [Google Scholar]
  5. Barbeau A., Campanella G., Butterworth R. F., Yamada K. Uptake and efflux of 14-C-dopamine in platelets: evidence for a generalized defect in Parkinson's disease. Neurology. 1975 Jan;25(1):1–9. doi: 10.1212/wnl.25.1.1. [DOI] [PubMed] [Google Scholar]
  6. Beardsley J. V., Puletti F. Personality (MMPI) and cognitive (WAIS) changes after levodopa treatment. Arch Neurol. 1971 Aug;25(2):145–150. doi: 10.1001/archneur.1971.00490020063007. [DOI] [PubMed] [Google Scholar]
  7. Bowers M. B., Jr Central dopamine turnover in schizophrenic syndromes. Arch Gen Psychiatry. 1974 Jul;31(1):50–54. doi: 10.1001/archpsyc.1974.01760130034005. [DOI] [PubMed] [Google Scholar]
  8. Brown G. L., Wilson W. P. Parkinsonism and depression. South Med J. 1972 May;65(5):540–545. doi: 10.1097/00007611-197205000-00008. [DOI] [PubMed] [Google Scholar]
  9. CARLSSON A., LINDQVIST M. EFFECT OF CHLORPROMAZINE OR HALOPERIDOL ON FORMATION OF 3METHOXYTYRAMINE AND NORMETANEPHRINE IN MOUSE BRAIN. Acta Pharmacol Toxicol (Copenh) 1963;20:140–144. doi: 10.1111/j.1600-0773.1963.tb01730.x. [DOI] [PubMed] [Google Scholar]
  10. CARLSSON A. The occurrence, distribution and physiological role of catecholamines in the nervous system. Pharmacol Rev. 1959 Jun;11(2 Pt 2):490–493. [PubMed] [Google Scholar]
  11. Chase T. N., Ng L. K., Watanabe A. M. Parkinson's disease. Modification by 5-hydroxytryptophan. Neurology. 1972 May;22(5):479–484. doi: 10.1212/wnl.22.5.479. [DOI] [PubMed] [Google Scholar]
  12. Cotzias G. C., Papavasiliou P. S., Gellene R. Modification of Parkinsonism--chronic treatment with L-dopa. N Engl J Med. 1969 Feb 13;280(7):337–345. doi: 10.1056/NEJM196902132800701. [DOI] [PubMed] [Google Scholar]
  13. EHRINGER H., HORNYKIEWICZ O. [Distribution of noradrenaline and dopamine (3-hydroxytyramine) in the human brain and their behavior in diseases of the extrapyramidal system]. Klin Wochenschr. 1960 Dec 15;38:1236–1239. doi: 10.1007/BF01485901. [DOI] [PubMed] [Google Scholar]
  14. GOLDBERG L. R. DIAGNOSTICIANS VS. DIAGNOSTIC SIGNS: THE DIAGNOSIS OF PSYCHOSIS VS. NEUROSIS FROM THE MMPI. Psychol Monogr. 1965;79:9–928. doi: 10.1037/h0093885. [DOI] [PubMed] [Google Scholar]
  15. Godwin-Austen R. B., Tomlinson E. B., Frears C. C., Kok H. W. Effects of L-dopa in Parkinson's disease. Lancet. 1969 Jul 26;2(7613):165–168. doi: 10.1016/s0140-6736(69)91417-2. [DOI] [PubMed] [Google Scholar]
  16. Hoehn M. M., Yahr M. D. Parkinsonism: onset, progression and mortality. Neurology. 1967 May;17(5):427–442. doi: 10.1212/wnl.17.5.427. [DOI] [PubMed] [Google Scholar]
  17. Hoeldtke R., Rogawski M., Wurtman R. J. Effect of selective destruction of central and peripheral catecholamine-containing neurones with 6-hydroxydopamine on catecholamine excretion in the rat. Br J Pharmacol. 1974 Feb;50(2):265–270. doi: 10.1111/j.1476-5381.1974.tb08571.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Janowsky D. S., el-Yousel M. K., Davis J. M., Sekerke H. J. Provocation of schizophrenic symptoms by intravenous administration of methylphenidate. Arch Gen Psychiatry. 1973 Feb;28(2):185–191. doi: 10.1001/archpsyc.1973.01750320023004. [DOI] [PubMed] [Google Scholar]
  19. Korf J., van Praag H. M. Retarded depression and the dopamine metabolism. Psychopharmacologia. 1971;19(2):199–203. doi: 10.1007/BF00402643. [DOI] [PubMed] [Google Scholar]
  20. Kott E., Bornstein B., Eichhorn F. Excretion of dopa metabolites. N Engl J Med. 1971 Feb 18;284(7):395–395. doi: 10.1056/nejm197102182840725. [DOI] [PubMed] [Google Scholar]
  21. LEVITA E., RIKLAN M., COOPER I. S. COGNITIVE AND PERCEPTUAL PERFORMANCE IN PARKINSONISM AS A FUNCTION OF AGE AND NEUROLOGICAL IMPAIRMENT. J Nerv Ment Dis. 1964 Dec;139:516–520. doi: 10.1097/00005053-196412000-00003. [DOI] [PubMed] [Google Scholar]
  22. Marsh G. G., Markham C. H. Does levodopa alter depression and psychopathology in Parkinsonism patients? J Neurol Neurosurg Psychiatry. 1973 Dec;36(6):925–935. doi: 10.1136/jnnp.36.6.925. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Matthysse S. Antipsychotic drug actions: a clue to the neuropathology of schizophrenia? Fed Proc. 1973 Feb;32(2):200–205. [PubMed] [Google Scholar]
  24. Nybäck H., Borzecki Z., Sedvall G. Accumulation and disappearance of catecholamines formed from tyrosine-14C in mouse brain; effect of some psychotropic drugs. Eur J Pharmacol. 1968 Nov;4(4):395–403. doi: 10.1016/0014-2999(68)90025-3. [DOI] [PubMed] [Google Scholar]
  25. Owen D. A., Marsden C. D. Effect of adrenergic beta-blockade on parkinsonian tremor. Lancet. 1965 Dec 18;2(7425):1259–1262. doi: 10.1016/s0140-6736(65)92279-8. [DOI] [PubMed] [Google Scholar]
  26. Rutledge C. O., Hoehn M. M. Sulphate conjugation and L-dopa treatment of Parkinsonian patients. Nature. 1973 Aug 17;244(5416):447–450. doi: 10.1038/244447b0. [DOI] [PubMed] [Google Scholar]
  27. SINES L. K., SILVER R. J. An index of psychopathology (Ip) derived from clinicians' judgments of MMPI profiles. J Clin Psychol. 1963 Jul;19:324–326. doi: 10.1002/1097-4679(196307)19:3<324::aid-jclp2270190323>3.0.co;2-p. [DOI] [PubMed] [Google Scholar]
  28. SOURKES T. L., DENTON R. L., MURPHY G. F., CHAVEZ B., SAINT CYR S. The excretion of dihydroxyphenylalanine, dopamine, and dihydroxyphenylacetic acid in neuroblastoma. Pediatrics. 1963 Apr;31:660–668. [PubMed] [Google Scholar]
  29. Sato T. L. The quantitative determination of 3-methoxy-4-hydroxyphenylacetic acid (homovanillic acid) in urine. J Lab Clin Med. 1965 Sep;66(3):517–525. [PubMed] [Google Scholar]
  30. Seeman P., Lee T. Antipsychotic drugs: direct correlation between clinical potency and presynaptic action on dopamine neurons. Science. 1975 Jun 20;188(4194):1217–1219. doi: 10.1126/science.1145194. [DOI] [PubMed] [Google Scholar]
  31. Snyder S. H., Banerjee S. P., Yamamura H. I., Greenberg D. Drugs, neurotransmitters, and schizophrenia. Science. 1974 Jun 21;184(4143):1243–1253. doi: 10.1126/science.184.4143.1243. [DOI] [PubMed] [Google Scholar]
  32. Vidi A., Bonardi G. Simple quantitative method for determining 3-methoxy-4-hydroxyphenylacetic acid and 3,4-dihydroxyphenylacetic acid in urine. Clin Chim Acta. 1972 May;38(2):463–464. doi: 10.1016/0009-8981(72)90141-6. [DOI] [PubMed] [Google Scholar]
  33. Vogt M. Functional aspects of the role of catecholamines in the central nervous system. Br Med Bull. 1973 May;29(2):168–172. doi: 10.1093/oxfordjournals.bmb.a070989. [DOI] [PubMed] [Google Scholar]
  34. Weil-Malherbe H. The estimation of total (free + conjugated) catecholamines and some catecholamine metabolites in human urine. Methods Biochem Anal. 1968;16:293–326. doi: 10.1002/9780470110348.ch6. [DOI] [PubMed] [Google Scholar]
  35. Weil-Malherbe H., Van Buren J. M. The excretion of dopamine and dopamine metabolites in Parkinson's disease and the effect of diet thereon. J Lab Clin Med. 1969 Aug;74(2):305–318. [PubMed] [Google Scholar]
  36. Yahr M. D., Duvoisin R. C., Hoehn M. M., Schear M. J., Barrett R. E. L-Dopa (L-3,4-dihydroxyphenylanine)--its clinical effects in parkinsonism. Trans Am Neurol Assoc. 1968;93:56–63. [PubMed] [Google Scholar]
  37. Yahr M. D., Duvoisin R. C., Schear M. J., Barrett R. E., Hoehn M. M. Treatment of parkinsonism with levodopa. Arch Neurol. 1969 Oct;21(4):343–354. doi: 10.1001/archneur.1969.00480160015001. [DOI] [PubMed] [Google Scholar]

Articles from Journal of Neurology, Neurosurgery, and Psychiatry are provided here courtesy of BMJ Publishing Group

RESOURCES